Previous close | 215.00 |
Open | 214.20 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 214.20 - 215.20 |
52-week range | 199.20 - 273.80 |
Volume | |
Avg. volume | 160,879 |
Market cap | N/A |
Beta (5Y monthly) | 0.23 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 24 Oct 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Sobi® today announced the publication of full results from the Phase 3 XTEND-Kids study in The New England Journal of Medicine (NEJM) confirming the safety and efficacy profile of ALTUVOCT® (efanesoctocog alfa), in children younger than 12 years old with severe haemophilia A. The study demonstrated that fixed-dose once-weekly prophylaxis with ALTUVOCT, a new class of high-sustained factor VIII therapy, provided highly effective bleed protection in children.
Second Quarter 2024
The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 14 May 2024, resolved - for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programmes resolved by the Annual General Meeting - on directed share issues of no more than 1,641,103 redeemable and convertible class C shares.